Urological Applications of Botulinum Toxin A by Yaiesh, Said M. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 8
Urological Applications of Botulinum Toxin A
Said M. Yaiesh, Meshari F. Almutairi,
Abdullatif E. Al-Terki and Tariq F. Al-Shaiji
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.79555
Abstract
Botulinum toxin A (BoNT-A) has seen in the last two decades an increased level of
application in urological practice, first FDA approved in 2011 for neurogenic detrusor
overactivity and then later in 2013 for refractory overactive bladder. Hundreds of studies
have been published in literature assessing the chemical structure of botulinum toxins and
how urothelial injections in the lower urinary tract and vesical instillations can be
employed in the management of a spectrum of urological conditions particularly voiding
dysfunction. The consensus is still out on toxin A preparations, mode and pattern of
application whether instilled or injected intradetrusally, units used, as well as time to
onset and duration of effect of injections and is still a dense research topic. This is reflected
in the continuously changing and differing grades of recommendations between societies
of urological practitioners such as the EAU and AUA, among others. This chapter dis-
cusses both the FDA-approved and experimental applications of botulinum toxin A in
urology, indications, techniques, and points of debate.
Keywords: overactive bladder, neurogenic detrusor overactivity, intradetrusor injections,
voiding dysfunction
1. Introduction
Urological applications of botulinum toxins are not new, but their approval and mass use are
overdue. Though it was first used safely on humans in the 1970s, the journey for emergence of
the urological uses of botulinum toxin isolates was only recognized in the first decade of the
twenty-first century. The introduction of the use of botulinum toxin type A (BoNT-A) in its
various preparations revolutionized and extended the spectrum of conservative and mini-
mally invasive treatment modalities of a spectrum of voiding and sexual dysfunction condi-
tions. Despite that, and although it is being increasingly recognized in guidelines, botulinum
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toxin remains of limited approval in urological applications by regulatory bodies such as the
US Food and Drug Administration.
The general principles of the mechanism of action of botulinum toxins apply similarly in
urological applications of the toxin. By binding presynaptically to sites on the cholinergic
nerve terminals, it decreases the release of acetylcholine causing a level of neuromuscular
blockade. This initially relaxes whichever muscular site is injected, commonly being the blad-
der intradetrusally, leading to relaxation of the target muscle injected by exerting an effect on
the efferent detrusor pathways. In the case of the detrusor muscle, this will lead to a decrease
in its contractions and increase in accommodative capacity. Eventually, the effect of the toxin
wears off, to which the hypotheses of how are varied, and the injections are to be repeated if
the desirable effect is to be achieved.
In literature, the use of botulinum toxin in urology was first described in 1988 for the treatment
of detrusor sphincter dyssynergia and gained momentum in more trials in the late 1990s. The
studies concentrated on the use of botulinum toxin type A, with little to no evidence showcas-
ing the effect of other types. The experimental applications first concentrated on treating
voiding dysfunction disorders, especially those of neurogenic causes such as spinal cord injury
and multiple sclerosis, and later went on to include the management of lower urinary tract
symptoms and chronic pelvic pain. Though first initially US FDA approved for human appli-
cation in 1989, it was not until 2011 that the FDA approved onabotulinumtoxinA (BoNT-A)
(BOTOX®; Allergan; Irvine, California) for the treatment of urinary incontinence and detrusor
overactivity secondary to neurological conditions such as spinal cord injury where conserva-
tive therapy with anticholinergic medication was inadequate or intolerable. BoNT-A was later
then approved for treatment of overactive bladder symptoms in adults with an inadequate
response to anticholinergic medication [1].
Estimates of the burden of urological conditions such as overactive bladder have varied in
published reports. In one review, it was estimated that around 16% of adults in the USA
experienced some degree of urgency symptoms with or without incontinence, irrespective of
gender [2]. This number contrasts greatly to that deduced from a Finnish study published
earlier and conducted in a similar manner where the prevalence of overactive bladder symp-
toms among adults was estimated at around 8% of the surveyed population [3]. Irrespective of
the prevalence, the US drug market for overactive bladder medication was placed at USD 3
billion, including anticholinergic medication and beta-agonists [4]. This market does not
include the US reported sales of USD 1.38 billion for Botox Therapeutic, the neuroscience and
urology division of Allergan which is the parent company of BOTOX concerned with the
treatment of chronic migraines, urological conditions, and others [5]. With an average price
tag of around USD 1300 per cycle of BOTOX injection intradetrusally on average three to four
times the price of a 30-day supply of anticholinergic medication, questions had to be raised on
the cost-effectiveness of this mode of intervention.
In 2006, a study from the UK demonstrated that BoNT-A injections for overactive bladder
irrespective of the pathology were more cost-effective over a 1-year duration than standard
care with regular office follow-ups and anticholinergic medication or clean self-intermittent
catheterization. This effectiveness was reproduced by other studies from the USA, Europe, and
the UK for a 5-year cost-effective and sensitivity analysis comparing BoNT-A injections to
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conservative management and surgical intervention [6–9]. All of this economic evidence,
coupled with numerous trials demonstrating the effectiveness of botulinum injections for
treatment of overactive bladder symptoms and other emerging uses, has popularized its
application among urologists and has led to its inclusion as second- and third-line manage-
ment modality in numerous urology care guidelines reviewed and published by authorities
such as the European Association of Urology (EAU), American Urological Association (AUA),
and International Continence Society (ICS).
This chapter will review the urological applications of botulinum toxin, particularly toxin type
A, the different injection modes, and FDA supported, guideline supported and emerging,
experimental, or deemed “off-label” uses.
1.1. Mechanism of action of botulinum injections in the urinary tract
In general, botulinum toxin is a very potent neuromuscular blocker. Each serotype exerts the
neuromuscular effect by working on a different molecular level. For example, botulinum
serotype A works by cleaving SNAP-25, a presynaptic protein involved in the fusion of
vesicle-containing neurotransmitters, while serotype B exerts its effects to another vesicle-
associated membrane protein (VAMP). This chapter will not discuss the molecular details of
each serotype, and most effects and mechanisms of action mentioned will pertain to serotype
A which is the most common serotype used for intradetrusor injections.
1.1.1. Botulinum injection in the bladder
In the bladder, as in other injection sites, botulinum toxin primarily acts by binding in presyn-
aptic targets impairing acetylcholine release and thus decreasing detrusor muscle contractions
by reducing the amount of acetylcholine that binds with M2 and M3 muscarinic receptors in
the detrusor muscle [10, 11]. Thus, it achieves its main function by relaxing the detrusor
muscle. However, many studies have proposed and to an extent showed evidence that
intradetrusor botulinum toxin injections, particularly toxin A, achieve relief from certain
chronic symptoms of detrusor overactivity and pain through several other mechanisms:
1. Other than through exerting a direct effect on motor function of the bladder muscle, it has
an indirect sensory effect via afferent sensory pathways of the urinary bladder. Botulinum
toxin injections reduce levels of sensory reception in the bladder suburothelium and, in
turn, desensitize to an extent the afferent output by unmyelinated C-fibers that arise
because of the damage to the pathways consisting of myelinated Aδ fibers usually carrying
signals to higher brain regions involved in micturition. This eventually results in reduction
of the activity of the spinal arc pathway that through activity of C-fibers causes detrusor
contractions [10, 12].
2. Researchers have demonstrated that botulinum toxin A also exerts a detrusor inhibitory
effect through inhibiting ATP release as well as acetylcholine. This was supported in both
animal and human bladder isolates with idiopathic detrusor overactivity [11].
3. Additionally, through inhibition of urothelial ATP release, research suggests that
intradetrusor botulinum injections may have antinociceptive effects not related to their
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effect on efferent nerves. In the case of chronic inflammation or neural injuries, this effect
could reduce sensitization in the bladder that provokes afferent activity usually causing
detrusor overactivity and, instead, leads to relaxation of the detrusor muscle [11, 13].
4. Inhibition of other neurotransmitter molecules and sensory receptors such as glutamate,
substance P, calcitonin gene-related peptide (CGRP), and TRPV1 has been demonstrated
in basic research and clinical trials, contributing to the sensory effect of botulinum bladder
injections [14].
5. A number of studies addressed the effects of botulinum injections on muscular composi-
tion in general and in the detrusor muscle specifically. In one study on injections of
botulinum toxin for cervical dystonia, repeated type A injections lead to some minor
muscle fiber alterations proposed to later cause muscle weakness [15]. In the urinary
bladder specifically, botulinum type A injections reduced fibrosis and bladder nerve
growth factor levels, but not necessarily the level of inflammation or edema [16, 17].
Cumulatively, botulinum injections in urothelial tissue result in relaxation of the detrusor mus-
cle. This effect is not immediate and is time-restrained by the induction and the slow recovery of
the neuromuscular junction plate from the paralytic effects of the injection. As the recovery
begins, the detrusor relaxation effects begin to decrease. For a maintained and sustained effect,
repeated injections are necessary. Unfortunately, recipients of repeated intradetrusor injections
do not always continue to exhibit similar responses to consecutive injections. A hypothesized
“secondary failure” phenomenon [18] has been addressed in literature for injections in the
bladder and in other sites, and the theoretical reasons attributed include the following:
1. Botulinum toxin injections have been shown to induce an immune response that results in
the production of antibodies that counter the effect of the toxin [19, 20].
2. Animal studies have demonstrated a reactive increase in production of intracellular pro-
teins after repeated injections of the toxin, possibly in a cellular effort to counter the effect
of the injections [21].
3. Microscarring of injection sites, hypothetically, though recent literature rebutted this the-
ory by demonstrating no significant detrusor muscle ultrastructure alterations after injec-
tions [22].
It is worth mentioning that there also are several studies that counter the hypothesis of
diminished effect on repeated injections. The EAU guidelines side with such studies based on
randomized controlled trials (RCTs) that showcased sustained efficacy on repeated injections
of onabotulinumtoxin A [23]. The frequency of subsequent intradetrusor injections will be
discussed onward in this chapter.
1.1.2. Botulinum injections in the urethra
BoNT-A injections in the urethra particularly at the level of the urethral sphincter have been
demonstrated to reduce sphincteric tone and urethral pressure. The mechanism of action is
likely similar to the action of botulinum toxin injections in detrusor muscle.
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1.1.3. Botulinum injections in the prostate
The effects of BoNT-A injections in the prostate have been demonstrated through a number of
clinical trials in both humans and animals. In rats, botulinum toxin injections resulted in
activation of apoptosis inducing prostatic atrophy. This was also demonstrated in clinical trials
where apoptosis was identified at both the stromal and epithelial levels of prostatic tissue after
BoNT-A injections, which reduced prostatic tissue mass, and was shown to reduce prostatic
urethral pressure [24–27].
1.2. Botulinum toxin serotypes and preparations in urology
There are seven different serotypes of botulinum toxins with several different properties and
preparations. Commercially available preparations of serotypes A and B have been approved
for human use, but their urological application has been limited. These include, but are not
limited to, two botulinum toxin type A preparations, onabotulinumtoxinA commercially
known as BOTOX® and distributed in the USA and abobotulinumtoxinA more widely known
as Dysport® (Galderma; Ipsen; Paris, France). These two preparations have been extensively
studied in literature and trials of urological applications. There are a few reports that com-
pared the potency and efficacy of these two preparations of serotype A.
It should be noted there are other BoNT-A preparations and, along with other serotypes except
for one preparation of serotype B, have not been in significant trials for application in urologi-
cal conditions. The reasons may be the unavailability of these serotypes in abundant commer-
cial quantities or, in some cases like serotype F which has a short duration of action, may be
deemed impractical or ineffective for intradetrusor injections, especially when considering the
desired durable neuromuscular effect by botulinum injections in the bladder detrusor muscle
[11, 28]. Similarly, one preparation of serotype B has been shown to exhibit effects of a shorter
duration than onabotulinumtoxinA and abobotulinumtoxinA, though not in direct compari-
son [29].
BOTOX® is FDA approved for use in neurogenic detrusor overactivity and refractory overac-
tive bladder where anticholinergic medication failed to resolve symptoms of frequency,
urgency, and urge urinary incontinence satisfactorily or were intolerable by patients. In con-
trast, Dysport® is yet to be FDA approved for any urological application or included in the
guidelines [30]. However, that has not limited its inclusion in a substantial number of trials for
different applications including overactive bladder, idiopathic and neurogenic, as well as
bladder pain syndrome, among others. Though both formulations are toxin A serotypes, they
differ in their preparation and extraction methods and molecular characteristics. Hence, there
are differences in quantitative dosage and potentially potency, which will be covered in a
subsequent section of this chapter.
There are also other commercially available formulations of BoNT-A: incobotulinumtoxinA,
marketed as Xeomin® by the German company Merz Pharmaceuticals and Chinese BTX-A
marketed as Prosigne®, among others. These preparations, along with botulinum toxin B
preparation rimabotulinumtoxinB (Myobloc®, Solstice Neurosciences Inc., San Francisco,
USA), are much less extensively investigated in urology literature and research but have been
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utilized experimentally for certain applications. Additionally, two more new preparations of
botulinum toxin A are on the horizon, including Evolus’ DWP-450 (Irvine, California, USA),
expected to undergo review by the FDA in 2018 and Revance Therapeutics’ RT-002 (Newark,
California, USA) whose FDA application filing is expected in 2019 [5]. Though yet far from
being introduced commercially, research into their urological uses would not be surprising.
Recently, BoNT-A preparations have been augmented with added substances thought to
improve the delivery and potency of the injections. Of these preparations were liposomal
activated preparations, which have been experimented for different urological applications.
The consensus is still not drawn, but data suggests no difference in efficacy or potency or need
for repeat injections.
1.3. Dosage and potency
Research has extensively investigated the different dosages and regimens for botulinum toxin
A injections in the urinary bladder. Differences were identified according to the preparation, as
is the case between onabotulinumtoxinA and abobotulinumtoxinA, as well as the quantity of
toxin per unit of each preparation measured using different modalities and the clinical impli-
cation this may have. Difference in dosing also exists for each condition and in recommenda-
tions and guidelines by different advisory bodies. It should be noted, however, that most
guidelines only describe injection doses of onabotulinumtoxinA (BOTOX®) since it is the only
FDA-approved formulation for some urological uses. Nevertheless, this has not limited
research into dosage and effects of abobotulinumtoxinA (Dysport®). Additionally, dilution of
the toxin and amount of liquid injected has varied, as well as the number of injection sites.
OnabotulinumtoxinA/BOTOX® comes in different dose formulations than abobotulinumtoxinA
(Dysport®). BOTOX® vials are available in 100 and 200 U, whereas Dysport® vials are available
in 300 and 500 U; researchers have, however, used higher doses of BOTOX® of up to 300 U. The
units for each preparation are not the same nor are they interchangeable. In general, 1 U of
BOTOX® is equivalent approximately to 3 U of Dysport®. However, these units are no indication
of the potency of either drug. Potency of BoNT-A has rather been described using other units,
including mouse units (MU) and median paralysis units (MPU), and the results of different
studies have not been successful in concluding which preparation is more potent than the other,
especially for bladder injections. It should be of note that the only FDA-approved doses for
BOTOX® are 100 U per setting for idiopathic overactive bladder and 200 U for neurogenic
detrusor overactivity. Higher doses of BOTOX® have not demonstrated clinically significant
efficacy in relation to a higher incidence of adverse effects [1, 31–34].
1.4. Injection modes and sites
Botulinum toxin injections have been described to be delivered to different tissues along the
lower urinary tract. In the bladder, literature investigated both intravesical instillations and
intradetrusor injections, with the latter proving to be more effective in achieving the therapeu-
tic effect of botulinum in the bladder. BoNT-A can also be delivered intrasphincterically to the
urethral sphincter, either periurethrally or even transperineally as some research describes, as
well as injected into the prostate.
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Literature and guidelines alike have described different numbers of injection sites in a tech-
nique called “mapping.” This entails injecting the toxin in a well-spread manner to a specific
number of sites on the cystoscopy. Of recent, the most commonly utilized number of injection
sites varies between 20 and 30 mapped sites, equally spread between the right and left
posterolateral walls of the bladder, with some sites injected more caudally. However, there
has been an avoidance for injection of botulinum toxin in the bladder trigone as hypothesis
suggests it may contribute to the development of retrograde ascension of urine from the
bladder to the kidney, known as vesicoureteric reflux. The consensus is out on whether this
hypothesis is valid; however, trigonal injections have been applied in botulinum injections for
bladder pain syndrome/interstitial cystitis with no reported occurrence of reflux [35, 36].
1.5. Injection techniques
1.5.1. Preparation of the toxin
To inject the botulinum toxin preparation, it must be first dissolved and diluted from its
powdered preparation in the storage vial. It is a surgeon’s preference for the dilutional amount
of normal saline solution to be used and depends on the number of injection sites the surgeon
plans on delivering the toxin through. In order to prepare 100 U of onabotulinumtoxinA for
injection, the surgeon usually injects 10 ml of sterile normal saline into the toxin vial and gently
swirls the vial to ensure completely dissolving the toxin powder. If 200 U are to be used, the
surgeon could use 5 ml for each 100 U vial or 10 ml for each vial [35, 36].
1.5.2. Endoscopic delivery
The toxin is delivered using an ultrafine needle placed through an introductory channel
element of the cystoscope device. Generally, the patient is under sedation or general anesthe-
sia, but injections under local anesthesia have been reported. A rigid or flexible cystoscope can
be used with equal effectiveness. The bladder is filled with irrigation fluid, and the needle is
mapped across the bladder urothelium to deliver a specific amount of the diluted toxin per
injection site. The amount delivered is dependent on the number of sites and amount of toxin
applied. Traditionally, injecting 100 U of onabotulinumtoxinA diluted in 10 ml of normal saline
over 20 sites yields an amount of 0.5 ml per injection, delivering 5 U of the toxin at each site,
delivered into the suburothelium or detrusor muscle.
Figure 1 provides a schematic presentation of the posterolateral view of the urinary bladder on
cystoscopy, 20 injection sites equally spread in a mapped scheme in each half of the wall. The
trigonal area, which stretches between the right and left ureteric orifices along an interorifice
ridge, is labeled and is usually spared unless indicated [35, 36].
1.6. Safety and adverse effects
Ever since its initial approval and application, the safety of botulinum injections has been front
and center and in a continuous debate. Botulinum toxin is considered one of the most potent
toxins to humans and, as such, the level of caution in utilizing it is understood. However, the
FDA and other regulatory bodies have approved its clinical application supported by a myriad
of clinical trials demonstrating both its safety and efficacy.
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In urological application, it has demonstrated to be a safe modality of treatment regardless of
which condition it is being utilized for.Numerous trials haveproven that the toxin does not seem
to systemically spread. One concern was spinal diffusion of the toxin after detrusor injection,
which has been debunked. It has also been proven that it does not cause any fibrotic or spastic
changes in the urothelium, which was hypothesized as a result of injections earlier on in its
application.
Though declared safe toxicologically, injection of the botulinum toxin A into the bladder urothe-
lium does result in certain adverse events, depending on the amount or dose injected and on the
disorder being treated. Common reported adverse events from the literature and acknowledg-
ment in guidelines include:
1. Bacteriuria and urinary tract infections. However, septic illness is not significantly reported.
2. Acute urinary retention in the setting of detrusor injections in rather incontinent patients.
Patients are usually counseled and consented prior to injection to the development of
urinary retention postinjection that it is probable, transient, and will require temporary
self-intermittent catheterization for an estimated period and a maximum of 2 weeks. In
subsequent repeat injections, some practitioners may opt to lower the injectable dose
below to what has resulted in urinary retention.
3. Limited hematuria.
Figure 1. Twenty mapped injection sites over the bladder urothelial posterolateral walls.
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1.7. Efficacy and follow-up
To deem botulinum injections as a viable treatment option for any urological condition with
established treatment modalities, it had to prove its efficacy, durability, and comparative benefit.
For each urological application, botulinum toxin A injections have been compared to established
standardized modalities of treatment. In the case of treatment for overactive bladder, for exam-
ple, intradetrusor BoNT-A injections provided a more cost-efficient and tolerable treatment
method according to some reviews. However, the injections had questions of durability.
Understanding the chemical effect of the injectable toxin, it was well understood that it was
time limited, and repeated injections will be required to attain and sustain the effect of the
injection. Questions of the safety of repeated injections were satisfactorily addressed in both
clinical trials and guidelines, with no evidence to warrant against it. However, reports of a
decreased effect after subsequent injections of the same preparation emerged on longer follow-
up trials, described as “secondary failure.” The rates of this failure are not high, and the data is
inconsistent. It should also be noted that urological conditions where botulinum toxin is
applied are mostly of a chronic nature, and repeated injections are associated with a higher
financial burden and operative morbidity for the patients; thus, it is reasonable to assume that
patients may opt for more definite treatment modalities even if they were more invasive.
It has been demonstrated that a positive response to botulinum toxin could be reachieved after
secondary failure by applying different preparations of BoNT-A or even using BoNT-B in
certain circumstances. However, this is all experimental and not endorsed or approved by the
FDA or any urological association.
Intradetrusor BoNT-A injections have been demonstrated to have an initial, subjectively, and
objectively reported effect starting at 2 weeks after the injection. Numerous studies demon-
strate a peak effect at 6 weeks postinjection. The effect is sustained variably, with reports
extending to 9 months or even a year, but the accepted consensus is that the effect does regress
at around 6 months postinjection. However, the frequency of reinjection to attain the effect is
not mandated by these numbers rigidly and shows interpatient differences. Thus, most practi-
tioners perform reinjections of the toxin on a patient-request basis. The time of onset and
length of the effect of intrasphincteric, paraurethral, and intraprostatic injections differ from
detrusor injections.
2. Urological applications
The urological applications of botulinum toxin A and B are numerous. As previously described,
the FDA approved the use of onabotulinumtoxinA for neurogenic detrusor overactivity in cases
of spinal cord injury or multiple sclerosis, idiopathic overactive bladder, and urge urinary
incontinence [1]. However, the guidelines and experimental uses have extended to include num-
erous other urological conditions.
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2.1. Neurogenic detrusor overactivity
Neurogenic detrusor overactivity (NDO) is defined as a spectrum of lower urinary tract
dysfunction symptoms that result from disruption of the neural control of the bladder, and
the term “neurogenic bladder” applies to the urinary bladder malfunction that ensues neural
dysfunction resulting from conditions affecting the nerves, including trauma as with spinal
cord injury, of which NDO is one entity and detrusor areflexia is another. The range of
symptoms includes bladder overactivity, urinary retention, or even both.
Symptoms of neurogenic detrusor overactivity vary according to the onset and cause, as well
as the level of the insult in the nervous system. They are generally divided into suprapontine
lesions, spinal cord lesions, and peripheral neuropathies. Table 1 lists the different common
causative entities of neurogenic bladder. Each disease results in a different combination of
symptoms of bladder dysfunction as a result of the neural pathway it affects and may result
in overactivity. Botulinum injections are indicated only when the detrusor muscle is overactive
as a result of the neural disease secondary to suprapontine and spinal cord injuries.
Whichever the causative neurological insult, quality of life measurement tools utilized in clinical
research unveil a debilitating entity of bladder overactivity encountered by NDO patients. When
the suprapontine neural pathways are affected, primitive voiding reflex arcs of the lower urinary
tract remain intact, and the bladder becomes overactive. Overactive bladder and spasticity can
result in frequency of urination, urgency, and urge urinary incontinence. If the external urinary
sphincter is affected and becomes hypotonic by the neural condition, stress urinary incontinence
or mixed urge-stress urinary incontinence may also occur.
Anticholinergic medications are the first line of therapy for neurogenic detrusor overactivity.
However, the use of these medications is sometimes limited by patient tolerability and require-
ment for high doses to achieve satisfactory results, and that is often accompanied by a higher
level of side effects. The EAU and ICS both recommend the use of botulinum toxin A injections
as a second line of management in agreement with the FDA approval. The recommendations
of the EAU are based on several randomized controlled trials that proved the efficacy of
intradetrusor injections of BoNT-A for the treatment of neurogenic bladder overactivity [36].
A summary of a number of these studies can be reviewed in Table 2.
The FDA recommends the injection of a maximum of 200 U of onabotulinumtoxinA
intradetrusally in the bladder for NDO. However, trials have reported injections of up to
Suprapontine lesions Spinal cord lesions Peripheral neuropathies
Cerebrovascular accidents (stroke) Spinal cord trauma above or below T6 level Diabetes mellitus
Parkinson’s disease Multiple sclerosis Neurosyphilis
Brain tumors Herpes zoster
Shy-Drager syndrome Lumbar disk herniation and surgery
Radical pelvic surgery
Table 1. Causes of neurogenic bladder.
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300 U for the control of the overactivity. Reports of higher dose efficacy being clinically
insignificant considering a higher level of adverse events and complications have steered the
consensus toward the FDA set dosage.
2.2. Idiopathic overactive bladder
Idiopathic or non-neurogenic overactive bladder (OAB) describes a syndromic set of symp-
toms of increased daytime and nighttime urination urgency and frequency with or without
urgency urinary incontinence in the absence of a causative pathology. In ICS definition, OAB is
a syndrome of urgency, a compelling sensation to urinate, frequency, or urinating more than
eight times during waking hours, and nocturia, waking up once or more to urinate at night;
Author Year Toxin Patient
population
Outcome Notes
Denys et al. 2017 Abobotulinum,
750 U, 15 or 30
injections,
trigone sparing
NDO and
incontinence
from SCI or
MS
Fifteen injection sites as effective
as 30 injection sites compared to
placebo
Kennelly
et al.
2017 Onabotulinum,
200 or 300 U,
trigone sparing
NDO patients Safe outcomes, similar effects
for both doses
Four-year follow-up study
Apostolidis
et al.
2013 Onabotulinum,
50, 100, and
200 U, trigone
sparing
NDO patients
with urge
incontinence
200 U dose most effective and
durable effect
Placebo controlled. Effect
reported at week 6
postinjection, measured for
52 weeks
Rovner
et al.
2013 Onabotulinum,
200 and 300 U,
trigone sparing
NDO due to
MS or SCI
with urgency
incontinence
Both doses achieved
comparable results in
improving urodynamic
outcomes of patients
Placebo-controlled phase III
trials
Sussman
et al.
2013 Onabotulinum,
200 and 300 U,
trigone sparing
NDO due to
MS or SCI
with urgency
incontinence
Both doses achieved
comparable results in
improving health-related
quality of life outcomes of
patients
Placebo-controlled, double-
blinded. Maximal effect
gained at week 6 postinjection
compared to placebo
Šámal et al. 2013 Onabotulinum,
300 U,
submucosally or
intradetrusorally
NDO patients Submucosal injections equally
effective
Ginsberg
et al.
2012 Onabotulinum,
200 or 300 U
NDO due to
MS or SCI
with urgency
incontinence
Both doses equally improved
the number of incontinence
episodes, cystometric
parameters, and quality of life
Placebo-controlled, double-
blinded, 52-week follow-up
Cruz et al. 2011 Onabotulinum,
200 or 300 U,
trigone sparing
NDO due to
MS or SCI
with urgency
incontinence
Both doses equally improved
the number of incontinence
episodes, cystometric
parameters, and quality of life
Placebo-controlled, double-
blinded. First effect
documented at 2 weeks
postinjection
Table 2. Summary of RCTs utilizing botulinum toxin in treatment of neurogenic detrusor overactivity [34, 37–43].
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whether urinary incontinence occurs as a result of the urgency (wet OAB) or does not (dry
OAB) is not essential for the clinical diagnosis.
Often, investigations for these presenting symptoms include performing a urodynamic evaluation
of the bladder,where a urinary catheter connected to pressure transducers is used to fill the bladder
with a saline solution in order to reproduce the urinary complaints of the patient; uninhibited
involuntary bladder contractions witnessed as a result of the filling or after the patient has voided
are defined as detrusor overactivity, which occurswith themajority of OAB patients. Nevertheless,
manypatientswith idiopathicOABdonot requireurodynamic assessmentwhen the symptomsare
clear-cut, and a number of clinical tools and scores can aid in diagnosing, assessing severity, and
following up of treatment efficacy of the syndrome. Refractory OAB is when symptoms fail to
resolve on conservativemanagementwith nonsurgical noninvasivemodalities.
Botulinum toxin A for the treatment of idiopathic refractory OAB was approved by the FDA in
2013, but only in the onabotulinumtoxinA/BOTOX preparation [1]. Clinical trials on both
onabotulinumtoxinA and abobotulinumtoxinA for the treatment of refractory OAB have pre-
ceded this approval, and to date, there is continuous investigation into the optimal dosage,
dilution, and frequency of injections to achieve optimal relief of the symptoms.
Though the ICS recommendations for the use BoNT-A for OAB refrain from specifying a certain
preparation, both the EAU and American Urology Association/Society of Urodynamics, Female
Pelvic Medicine and Urogenital Reconstruction (AUA/SUFU) guidelines specifically mention
onabotulinumtoxinA injections only.While the EAUguidelinesmention that abobotulinumtoxinA
and incobotulinumtoxinA are neither licensed nor interchangeable for onabotulinumtoxinA, the
AUAguidelines go a step further in adding a note on the use of abobotulinumtoxinA compared to
onabotulinumtoxinA. Citing one clinical trial that compared the efficacy of the two preparations,
the AUA/SUFU guidelines on management of non-neurogenic overactive bladder declare that
although abobotulinumtoxinA is of equal clinical efficacy, it is reported with a higher incidence of
postinjection adverse events when compared to onabotulinumtoxinA, particularly with regard to
the development of postinjection urinary retention requiring self-catheterization [44].
The recommended dose of onabotulinumtoxinA intradetrusor injection for idiopathic overac-
tive bladder in both the EAU and AUA guidelines is 100 U diluted in normal saline and
mapped across 20 injection sites. Both sets of guidelines discuss the possible rates of bacteriuria
postinjection, cautions of injection in elderly patients with OAB, and necessity of repeated
injections to sustain a desirable effect. The grade of recommendation for onabotulinumtoxinA
injection per the EAU guidelines is listed as grade A recommendation, supported by a com-
pelling set of randomized clinical trials, while the AUA gives the same treatment modality a
standard level of recommendation with a grade B strength of evidence where the benefits of
the injection outweigh the risks.
2.3. Detrusor sphincter dyssynergia
Normally, when the bladder contracts, there is a synergistic neural communication that relaxes
the sphincter responsible for control of the bladder outlet. This coordination allows the bladder
to perform its storage and emptying functions. However, any disruption to this synergy causes
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voiding dysfunction. Certain neurological conditions affecting the suprasacral micturition
centers, such as some of the causes listed in Table 1 like spinal cord trauma below the vertebral
level of T6, could lead to an entity of voiding dysfunction known as detrusor sphincter
dyssynergia (DSD). In DSD, the detrusor sphincter pathologically contracts simultaneously
with the detrusor muscle of the urinary bladder instead of relaxing to allow bladder emptying.
Thus, instead of free urinary flow during attempts of voiding, patients only pass small
amounts of urine, if any. Multiple sclerosis affecting the spinal cord could also result in DSD.
Botulinum toxin injection for the management of DSD was the first published urological
application of the toxin. Since its first description in 1988 by Dykstra, intrasphincteric botuli-
num injections for the management of DSD have been the focus of many researchers and
urologists [45]. However, the clinical guidelines such as those published by the ICS and EAU
do not dive into details for recommending this modality of managing DSD in neurogenic
bladder patients since it is not registered for such an application, but rather mention it as a
possible entity of treatment and make no specifications on the dosage or frequency of injec-
tions. The EAU based its limited recommendation on a Cochrane review that concluded that
more RCTs are necessary before further recommending intrasphincteric botulinum injections
for DSD but acknowledged reports stating its effectiveness. It should be mentioned, however,
that the literature describes different techniques for intrasphincteric and periurethral injections
of BoNT-A for the treatment of DSD, including transurethral endoscopic injections and
imaging-assisted transperineal approaches, with variable reported outcomes.
2.4. Other neurogenic and non-neurogenic voiding dysfunctions
Lower urinary tract symptoms can also be attributed to asynchrony between the detrusor and
sphincteric muscles and over- or underactivity of either the bladder detrusor muscle or urethral
sphincter. This may be an entity of dysfunction voiding, idiopathic or even neurogenic, such as
the peripheral neuropathy causes listed in Table 1. Successful treatment of DSD with sphincteric
BoNT-A injections allowed an insight into the treatment of these voiding dysfunction entities. It
has been demonstrated to decrease patient reliance on self-catheterization and improve voiding
efficiency. However, the data is experimental, and the modes, dosage, and frequencies vary, in
the absence of a consensus or clear recommendation by regulatory bodies like the EAU or AUA.
2.4.1. Fowler’s syndrome
Fowler’s syndrome is a unique entity of voiding dysfunction. Usually affecting young women,
it is defined as a disorder of urethral sphincter relaxation and urinary retention in volumes
reaching up to 1 l of urine, often in the absence of sensation of bladder fullness. Though its
etiology is not well understood, the introduction of sacral neuromodulation has provided a
means for restoring the normal voiding function in patients of Fowler’s syndrome. Guidelines
on the treatment of this syndrome with intrasphincteric injections of botulinum toxin are not
available, nor is there any consensus or panel discussion. However, an open-label study in
2015 reevaluated this modality of treatment after an unsuccessful trial 20 years prior. This
recent trial reignited interest into a less invasive modality of treatment of this syndrome
compared to sacral neuromodulation.
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2.5. Bladder pain syndrome/interstitial cystitis
This chronic debilitating condition was first described over 200 years ago. The hallmark of this
condition is “bladder pain” or suprapubic pain that the patient can specifically attribute its sensa-
tion in the bladder. Different terms have been used to describe the combination of suprapubic pain,
urgency, and frequency, in the absence of an infective pathology. Originally named interstitial
cystitis only, the term bladder pain syndrome was added to further describe this disease entity
wheremacroscopic findingsmaybeabsent on cystoscopic examinationof thebladder. Similarly, the
disease has been also termed hypersensitive bladder for the same reason.Nevertheless, a subgroup
of the disease exhibits positive cystoscopic findings of what is known as “Hunner’s lesions.” These
lesions, originally thought to beulcers in the bladdermucosa butproven otherwise, constitutewhat
is more known as the “classic” or “ulcerative” type of bladder pain syndrome/interstitial cystitis
(BPS/IC), and although first described inwomen, the disease afflicts both genders.
Treatment of this disease is as complex as its pathology. With an unknown cause, the aim of
treatment for the most part has concentrated on symptomatic relief and prolonged periods of
remission of the pain in between flares of the disease. Different modalities have been described
for the treatment of the disease, with varying degrees of success, ranging from oral amitripty-
line to surgical interventions. In the presence of Hunner’s lesions, there are numerous reports
of achievement of some degree of pain relief on resection and ablation of these lesions.
However, the other lower urinary tract symptoms may not be limited.
Botulinum toxin injections have been extensively described in the literature as a modality of
treating the symptoms of BPS/IC. First described by Smith et al. in 2004, it was reported to
provide relief from the bladder pain. Research then demonstrated the effects of BoNT-A
injections on the bladder in BPS/IC. On the microscopic level, BoNT-A in BPS/IC was shown to:
1. Decrease acetylcholine and noradrenaline release from nerves in the urothelium.
2. Decrease the level of TRPV1, which is typically elevated in BPS/IC in the bladder urothelium.
3. Decrease the levels of nerve growth factor (NGF).
4. Decrease the level of neurogenic inflammation.
5. Decrease the expression of P2X3 receptors and CGRP release.
6. Modulation of the release of inflammatory mediators from the bladder urothelium, typi-
cally upregulated in BPS/IC.
7. Decrease mast cell infiltration and apoptotic cell counts in the urothelium.
These cellular effects have been both demonstrated and reproduced in several studies; how-
ever, there was no consensus or standardization on the dose of BoNT-A injected and modali-
ties employed to augment the injections. Nevertheless, the described effects included:
1. Marked decrease in bladder and suprapubic pain.
2. Decrease in daytime and nighttime urinary frequency.
3. Decrease in the ICSI symptom score, an index used to assess the severity of the symptoms
of patients diagnosed with BPS/IC.
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4. An improvement in the quality of life of injected patients.
5. An increase in the maximal bladder capacity of urinary storage known as cystometric
capacity.
6. Decrease in urgency and desire to void.
7. Antinociceptive effect.
BoNT-A injections for bladder pain syndrome is not FDA approved. However, the data is
compelling enough from many randomized control trials that the ICS, EAU, and AUA sought
to include its application in their guidelines. Though the grades of recommendation differ in
strength, BoNT-A injections for the symptomatic treatment of BPS/IC are recognized as a viable
option. The EAU strongly recommends the use of BoNT-A injections for BPS/IC when more
conservative measures have failed and lists in sequence the different modalities it can be used in.
The AUA has a more modest recommendation for BoNT-A in BPS, listing it as a fourth-line
management modality.
Both onabotulinumtoxinA and abobotulinumtoxinA have been utilized in trials of treatment of
BPS/IC. There is no consensus in both the literature and the guidelines on the dose of BoNT-A to
be used. It should be of note that many trials, along with the EAU guidelines on management of
BPS/IC, describe an entity of management known as hydrodistension, used alone or in combina-
tion with BoNT-A injections. During hydrodistension, the bladder is filled with a considerable
amount of irrigation fluid and left in the bladder for an amount of time ranging between 5 and
15 minutes. The EAU proposes in its treatment algorithm that hydrodistension can be tried
alone, then submucosal BoNT-A injections with hydrodistension, and, finally, intradetrusal
BoNT-A injections with hydrodistension, without specifying the injectable dose or duration of
distension, reflecting the variance in the data. Additionally, trigonal-involving BoNT-A injections
have been described in the treatment of BPS/IC without inducing vesicoureteric reflux and with
a considerable efficacy.
2.6. Chronic pelvic pain syndrome
This broad term describes a spectrum of disorders including chronic prostatitis, which is
dubbed in some guidelines as the male variant of bladder pain syndrome. As with BPS/IC,
chronic pelvic pain syndrome (CPPS) is of a noninfective etiology with a significant effect on
the quality of life of the afflicted patient. A number of trials described decreased levels of pain
on both periurethral and transperineal injections of BoNT-A for the treatment of CPPS. The
EAU guidelines do not specify a recommendation for BoNT-A into the pelvic floor or prostate
for CPPS and describe it as having a “modest” effect, while the AUA pairs treatment of BPS/IC
and CPPS modalities in its recommendations.
2.7. Benign prostatic enlargement
The effects of intraprostatic injections of BoNT-A have been demonstrated in research on both
humans and animals and have supported the hypothesis that an induction in the apoptosis of
the glandular tissue of the prostate could lead to its atrophy and relief from the obstructive
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component of lower urinary tract symptoms that result from benign prostatic enlargement
(BPE). BPE could be thought of as a disease of age in men, where continuous proliferation of
the glandular tissue in the transitional zone of the prostate gland leads to an increase in its size
and narrows the outlet of the bladder, obstructing urinary flow. There is no specific sizable
enlargement that causes symptoms, and the degree of symptoms does not correlate to the size
of the enlarged prostate.
To date, the gold standard of treatment of BPE is transurethral resection of the prostate by
endoscopic measures, after standing the test of time against open prostatectomy and when
compared to emerging modalities of treatment. However, this has not deterred research into less
invasive modalities of treatment including pharmacological regimens using alpha-receptor
antagonists and 5-alpha reductase inhibitors, both first lines of treatment for BPE that have been
shown to offer symptomatic relief and delay the need for surgical intervention, and other
endoscopic and interventional radiology modalities.
Trials that have investigated intraprostatic injections of BoNT-A for BPE have described differ-
ent doses and modes of injection. Due to the multifactorial nature of the lower urinary tract
symptoms in BPE, prostatic BoNT-A injections may not provide complete or significant results
in the presence of associated bladder over- or underactivity as a result of the outlet obstruction
resulting from the prostatic enlargement. However, among those trials, there were clinically
significant results with injections into the prostate and the bladder neck, including:
1. Improvement in the maximal urinary flow rate of patients, known as the QMax on uroflow-
metric studies.
2. Reduction in symptomatic scoring indices used to assess severity of symptoms associated
with BPE.
Nevertheless, within these trials, the modes of injection and doses are different, and the results
are inconsistent and in some instances contradictory, indicating the need for further assess-
ment and more trials before a consensus could be made.
BoNT-A injections for the treatment of BPE are considered completely “off-label” and against
the EAU guidelines on the management of male lower urinary tract symptoms resulting from
BPE or benign prostatic obstruction. The EAU cites trials and a recent systemic review and
meta-analysis that showed BoNT-A not to be superior to placebo in the management of BPE
and, as such, recommends against the use of BoNT-A in BPE. The AUA, however, makes no
reference to or acknowledgment of BoNT-A prostatic injections.
2.8. Erectile dysfunction
Erectile dysfunction (ED) describes a spectrum of disorders in which a male cannot attain or
maintain an erection sufficient to perform penetrative intercourse or complete it to ejaculation.
The application of botulinum toxin injections in the treatment of entities of ED such as prema-
ture ejaculation and vasculogenic ED is reported in the literature of recent but are limited to
small clinical trials and case reports hypothesizing the effect of the toxin in improving the
sexual performance of the affected male. It is an area of future research and consideration,
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especially with certain animal trials showing complementation of the mechanism of action of
botulinum toxins and the physiology of attaining an erection.
3. Conclusion
Botulinum toxin applications in urology have garnered much attention in the last two decades
both on the research and regulatory levels. The effects of the toxin at the neurophysiological level
of the bladder urothelium extend beyond the neuromuscular blockade leading to detrusor
relaxation and have been proven to exert sensory, antinociceptive, and anti-inflammatory effects
as well through mediation of neural, cellular, and inflammatory markers. Though limited to the
use of botulinum toxin A with the exception of one preparation of botulinum toxin B, the
urological applications of botulinum are categorized into FDA-approved, guideline-supported,
and experimental or “off-label” uses. The FDA has approved the use of onabotulinumtoxinA
only and in the setting of neurogenic detrusor overactivity and refractory overactive bladder
after failed treatment with anticholinergic medications. Regulatory bodies like the EAU and
AUA not only adhered to this approval but also endorsed clinically apparent beneficial applica-
tions of BoNT-A in conditions like DSD and BPS/IC. Experimental and off-label uses are not
recommended but are still practiced with limited evidence.
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